Most of the major indices posted gains yesterday, with the S&P 500 and DJIA advancing more than 10%. The NASDAQ trailed behind with a 0.6% gain.
Today, futures are on the rise after U.S. and Chinese agreed to trade talks. The Chinese also said they’re interested ni holding up their terms of the Phase-One trade deal. Global stocks rose on the optimism.
U.S. Futures are pointing towards a higher open this morning. Asian stocks were mixed overnight but the Japaneses Nikkei :led with a 1.4% gain. European stocks are still trading, but they’re almost all in the green.
Today’s featured earnings slate includes Palo Alto Networks (PANW) after the bell.
These stocks are trading actively today.
Carnival Corp. (CCL)
Carnival Corp and other cruise stocks are on the rise today thanks to a series of positive headlines regarding coronavirus. Case counts are ticking lower, the FDA just approved a new treatment that could greatly reduce the fatality rate in sever cases, and a vaccine could be on the way. That’s all bullish for CCL because the sooner people stop worrying about coronavirus the sooner they can start cruising!
American Airlines (AAL)
American Airlines is moving higher today after it and other U.S. carriers are modifying their cleaning processes to make them safer and more effective. This could give travelers more peace of mind to travel and, if we get a vaccine any time soon, the new cleaning procedures might lead to a faster-than-expected recover.
AAL is trading actively and it’s up 2.5%.
VIVEVE MEDICAL INC. (VIVE)
This news just hit the market but here’s what we know so far. Viveve announce data from a SUI feasibility study that found positive outcomes from IN-VIVO pre-clinal study conducted to validate its new inert shame tip for use in pivot pursuit trail in the U.S.
This is breaking news so it’s all we have so far, but we’ll keep you posted. VIVE is the most active-premarket stock and its advancing 43.1%
OVID THERAPEUTICS INC (OVDI)
Ovid is on the rise after announcing a major equity offering that will generate more than $50 million in proceeds. The company will sell 6.25 million shares of its common stock a $8 per share.
Ovid Therapeutics intends to use the net proceeds from the Offering primarily to advance the clinical development program of OV935 for developmental and epileptic encephalopathies, the clinical development program of OV101 for Angelman syndrome and Fragile X syndrome and pre-commercialization activities for OV101, and the remainder of the net proceeds for working capital and general corporate purposes.
Ovid is trading actively on the news ant it’s up 35.0%